PUBLIC | NASDAQ:EDIT
Building the leading genome editing company dedicated to treating patients with genetically defined diseases.
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10)
Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.